Dan O'Day, Gilead CEO (Kevin Dietsch/UPI/Bloomberg via Getty Images)
April 6, 2021 07:23 AM EDT
People
Pharma

De­spite remde­sivir ap­proval and 2 big buy­outs, Gilead CEO Dan O'­Day sees pay fall 35% from 2019

Max Gelman

Senior Editor

For all in­tents and pur­pos­es, 2020 was a busy year for Gilead. The big biotech pulled off two big ac­qui­si­tions in Forty Sev­en and Im­munomedics …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times